Open AccessRandomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial
Author(s) -
Supachai RerksNgarm,
Punnee Pitisuttithum,
JeanLouis Excler,
Sorachai Nitayaphan,
Jaranit Kaewkungwal,
Nakorn Premsri,
Prayura Kunasol,
Nicos Karasavvas,
Alexandra Schuetz,
Viseth Ngauy,
Faruk Sinangil,
Peter Dawson,
Allan C. deCamp,
Sanjay Phogat,
Sanjay Garunathan,
James Tartaglia,
Carlos A. DiazGranados,
Silvia RattoKim,
Poonam Pegu,
Michael A. Eller,
Chitraporn Karnasuta,
David C. Montefiori,
Sheetal Sawant,
Nathan Vandergrift,
Saintedym Wills,
Georgia D. Tomaras,
Merlin L. Robb,
Nelson L. Michael,
Jérôme H. Kim,
Sandhya Vasan,
Robert J. O’Connell,
for the RV Study Team
Publication year - 2017
Publication title -
the journal of infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.69
H-Index - 252
eISSN - 1537-6613
pISSN - 0022-1899
DOI - 10.1093/infdis/jix099
Subject(s) - medicine , hiv vaccine , human immunodeficiency virus (hiv) , vaccine trial , virology , vaccine efficacy , aids vaccines , randomized controlled trial , vaccination , clinical trial , double blind , immunology , alternative medicine , placebo , pathology
The RV144 ALVAC-HIV prime, AIDSVAX B/E boost afforded 60% efficacy against human immunodeficiency virus (HIV) acquisition at 1 year, waning to 31.2% after 3.5 years. We hypothesized that additional vaccinations might augment immune correlates of protection.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom